Fluorescent Zn2+ sensors play a pivotal role in zinc biology, but their application in complex media such as blood serum or plate reader-based cellular assays is hampered by autofluorescence and light scattering. Bioluminescent sensor proteins provide an attractive alternative to fluorescent sensors for these applications, but the only bioluminescent sensor protein developed so far, BLZinCh, has a limited sensor response and a suboptimal Zn2+ affinity. In this work, we expanded the toolbox of bioluminescent Zn2+ sensors by developing two new sensor families that show a large change in the emission ratio and cover a range of physiologically relevant Zn2+ affinities. The LuZi platform relies on competitive complementation of split NanoLuc luciferase and displays a robust, 2-fold change in red-to-blue emission, allowing quantification of free Zn2+ between 2 pM and 1 nM. The second platform was developed by replacing the long flexible GGS linker in the original BLZinCh sensor by rigid polyproline linkers, yielding a series of BLZinCh-Pro sensors with a 3-4-fold improved ratiometric response and physiologically relevant Zn2+ affinities between 0.5 and 1 nM. Both the LuZi and BLZinCh-Pro sensors allowed the direct determination of low nM concentrations of free Zn2+ in serum, providing an attractive alternative to more laborious and/or indirect approaches to measure serum zinc levels. Furthermore, the genetic encoding of the BLZinCh-Pro sensors allowed their use as intracellular sensors, where the sensor occupancy of 40-50% makes them ideally suited to monitor both increases and decreases in intracellular free Zn2+ concentration in simple, plate reader-based measurements, without the need for fluorescence microscopy.
Fluorescent Zn2+ sensors play a pivotal role in zinc biology, but their application in complex media such as blood serum or plate reader-based cellular assays is hampered by autofluorescence and light scattering. Bioluminescent sensor proteins provide an attractive alternative to fluorescent sensors for these applications, but the only bioluminescent sensor protein developed so far, BLZinCh, has a limited sensor response and a suboptimal Zn2+ affinity. In this work, we expanded the toolbox of bioluminescent Zn2+ sensors by developing two new sensor families that show a large change in the emission ratio and cover a range of physiologically relevant Zn2+ affinities. The LuZi platform relies on competitive complementation of split NanoLuc luciferase and displays a robust, 2-fold change in red-to-blue emission, allowing quantification of free Zn2+ between 2 pM and 1 nM. The second platform was developed by replacing the long flexible GGS linker in the original BLZinCh sensor by rigid polyproline linkers, yielding a series of BLZinCh-Pro sensors with a 3-4-fold improved ratiometric response and physiologically relevant Zn2+ affinities between 0.5 and 1 nM. Both the LuZi and BLZinCh-Pro sensors allowed the direct determination of low nM concentrations of free Zn2+ in serum, providing an attractive alternative to more laborious and/or indirect approaches to measure serum zinc levels. Furthermore, the genetic encoding of the BLZinCh-Pro sensors allowed their use as intracellular sensors, where the sensor occupancy of 40-50% makes them ideally suited to monitor both increases and decreases in intracellular free Zn2+ concentration in simple, plate reader-based measurements, without the need for fluorescence microscopy.
Zn2+ is
an essential trace element that plays a key
role in many biochemical processes, including enzyme catalysis, the
regulation of gene expression, and intracellular signaling.[1−4] Given this importance, it is not surprising that zinc deficiency
is associated with severe risk of, among others, growth retardation,
neural dysfunctions, and imbalanced immune responses.[5−9] Approximately 17% of the global population is at risk of acquiring
zinc deficiency, in particular in low- and middle-income countries,[10,11] resulting in millions of disability-adjusted life years and thousands
of deaths among children under the age of five, every year.[12−14] Zinc deficiency is currently determined by measuring the total serum
Zn2+ concentration (12–16 μM in healthy people)
using expensive and technically complex instruments such as atomic
absorption spectroscopy (AAS) and inductively coupled plasma mass
spectrometry (ICP-MS).[15,16] In addition, it is unclear whether
total serum Zn2+ represents a good measure of the zinc
status, as almost all serum Zn2+ is tightly bound to plasma
proteins, such as albumin (80–90%) and α-2-macroglobulin
(10–20%).[17−19] The concentration of free Zn2+ may be
a more physiologically relevant biomarker, since it represents the
bioavailable part of the serum Zn2+.[19] However, simple and robust methods to measure the concentration
of free Zn2+ in serum and complex biological matrices are
currently lacking.The development of small-molecule fluorescent
probes and fluorescent
sensor proteins that measure intracellular free Zn2+ concentrations
has substantially contributed to our understanding of intracellular
Zn2+ homeostasis and signaling.[20−25] Genetically encoded, protein-based sensors have proven particularly
useful as they can be applied to measure fluctuations in free Zn2+ concentrations at specific subcellular locations in live
cells with minimal perturbation of the cell integrity. Most previously
developed Zn2+ sensor proteins are based on the modulation
of Förster Resonance Energy Transfer (FRET), resulting in a
ratiometric sensor output that is critical for reliable free Zn2+ quantification. A rich toolbox of fluorescent sensor proteins
has been developed, covering a wide range of Zn2+ affinities,
colors, and subcellular targeting. For example, the eCALWY, Zap, and
eZinCh2 families of Zn2+ sensors have been widely used
to measure intracellular free Zn2+ concentrations in cell
lines, primary cells, plants, and whole organisms.[21−23] A drawback
of fluorescence-based sensors is their dependence on external illumination,
which hinders long-term imaging due to photobleaching and phototoxicity.
Furthermore, fluorescent measurements in complex media such as blood
serum or plate reader-based cellular assays are severely hampered
by autofluorescence and light scattering. For these applications,
bioluminescent sensor proteins, based on the modulation of energy
transfer between a donor luciferase and an acceptor fluorescent domain
(BRET), provide attractive alternatives. We previously developed a
bioluminescent variant of the eZinCh2 sensor by introducing the luciferase
NanoLuc (NLuc) at the N-terminus of the Cerulean fluorescent donor
domain.[23,26,27] The resulting
BLZinCh-1 sensor allowed both fluorescent and bioluminescent detection,
showing a modest 30% change in the bioluminescence emission ratio
upon binding to Zn2+ (Figure A). The limited ratiometric response of the
BLZinCh-1 sensor could be increased to 50% by introduction of a chromophore-silencing
mutation in Cerulean, providing better spectral separation between
the donor and acceptor emission. However, the resulting BLZinCh-3
sensor also showed an increase in Zn2+ affinity to KD = 16 pM, which is suboptimal for measuring
intracellular cytosolic Zn2+ concentrations that are typically
in the 0.5–1 nM range.[22,23,28]
Figure 1
Bioluminescent
Zn2+ sensor protein platforms. (A) Schematic
representation of the concept of free Zn2+ detection using
the previously developed BLZinCh sensor proteins. BRET occurs from
NanoLuc (NLuc) to Cerulean, and in the presence of free Zn2+, the Zn2+-coordinating residues on the exterior of Cerulean
and Citrine (connected via a flexible GGS linker) bind to Zn2+, and FRET occurs from Cerulean to Citrine. This results in the emission
of yellow light. The BLZinCh sensors have a moderate maximal change
in the emission ratio (30–50%) and a suboptimal, high affinity
for Zn2+ (16–160 pM). (B) Overview of the LuZi platform.
The LuZi sensor proteins contain the two Zn2+-binding domains
Atox1 and WD4 and have a readout mechanism based on split NLuc complementation.
The NLuc large BiT (LB) is fused to two small BiTs (SB), with different
affinities for LB. A red-emitting Cy3 fluorophore (red star) is conjugated
to the higher affinity SB (SB2), resulting in a high BRET efficiency
in the absence of Zn2+. Binding of Zn2+ disrupts
the interaction of SB2 to LB, changing the emission from red to blue.
(C) Overview of the BLZinCh-Pro platform, where the original flexible
linker between Cerulean and Citrine in the BLZinCh sensors is replaced
with four different rigid polyproline linkers (50x, 40x, 30x, and
20x proline). These rigid linkers increase the distance between the
fluorescent proteins in the Zn2+-depleted state, resulting
in an increased maximal change in the emission ratio and an attenuated
affinity for Zn2+.
Bioluminescent
Zn2+ sensor protein platforms. (A) Schematic
representation of the concept of free Zn2+ detection using
the previously developed BLZinCh sensor proteins. BRET occurs from
NanoLuc (NLuc) to Cerulean, and in the presence of free Zn2+, the Zn2+-coordinating residues on the exterior of Cerulean
and Citrine (connected via a flexible GGS linker) bind to Zn2+, and FRET occurs from Cerulean to Citrine. This results in the emission
of yellow light. The BLZinCh sensors have a moderate maximal change
in the emission ratio (30–50%) and a suboptimal, high affinity
for Zn2+ (16–160 pM). (B) Overview of the LuZi platform.
The LuZi sensor proteins contain the two Zn2+-binding domains
Atox1 and WD4 and have a readout mechanism based on split NLuc complementation.
The NLuc large BiT (LB) is fused to two small BiTs (SB), with different
affinities for LB. A red-emitting Cy3 fluorophore (red star) is conjugated
to the higher affinity SB (SB2), resulting in a high BRET efficiency
in the absence of Zn2+. Binding of Zn2+ disrupts
the interaction of SB2 to LB, changing the emission from red to blue.
(C) Overview of the BLZinCh-Pro platform, where the original flexible
linker between Cerulean and Citrine in the BLZinCh sensors is replaced
with four different rigid polyproline linkers (50x, 40x, 30x, and
20x proline). These rigid linkers increase the distance between the
fluorescent proteins in the Zn2+-depleted state, resulting
in an increased maximal change in the emission ratio and an attenuated
affinity for Zn2+.In this work, we expand the toolbox of bioluminescent Zn2+ sensor proteins by developing two new sensor formats that show a
large change in the emission ratio and cover a range of physiologically
relevant Zn2+ affinities. The first platform (LuZi, Figure B) uses the Zn2+-binding receptor domains previously employed in the eCALWY
FRET sensors to control the competitive intramolecular complementation
of a split NLuc luciferase between a high BRET, Zn2+-free
state and a low BRET, Zn2+-bound state. A similar sensor
principle was recently successfully introduced to increase the performance
of BRET sensors for antibody detection, because it uses a red fluorescent
acceptor that is well separated from the NLuc emission.[29] The second platform (BLZinCh-Pro, Figure C) substantially improves upon
the performance of the BLZinCh sensors by replacing the flexible linker
separating the fluorescent domains by rigid polyproline linkers, simultaneously
decreasing BRET in the Zn2+-free state and subtly attenuating
the affinity into the more physiologically relevant ∼0.5–1
nM affinity range. These new sensors allow fast, robust, and sensitive
quantification of free Zn2+ concentrations, both in blood
serum samples and in the cytosol of mammalian cells.
Results and Discussion
LuZi:
Red-Blue Bioluminescent Zn2+ Sensors Based
on Split NanoLuc Complementation
In previous work, we already
explored the development of bioluminescent variants of the eCALWY
series of FRET sensors by fusing NLuc to the N-terminus of the Cerulean
fluorescent domain.[27] However, only very
small changes in the BRET ratio were observed for these sensors (<7%),
which is unfortunate as the Zn2+-binding part of the eCALWY
sensors can be readily tuned to bind Zn2+ with a range
of affinities between 2 pM and 5 nM.[22,30] The poor performance
of the eCALWY sensors is probably due to suboptimal energy transfer
from NLuc to Cerulean and direct BRET between NLuc and Citrine in
the absence of Zn2+. We therefore decided to take advantage
of a new design principle that does not rely on direct modulation
of BRET efficiency but is based on competitive intramolecular complementation
of split NLuc.[29] Split NLuc is composed
of the 18 kDa large BiT (LB) fragment and the 1.3 kDa small BiT (SB)
peptide whose interaction can be readily tuned between 0.7 nM and
190 μM.[31] In the herein developed
LuZi sensor, we genetically fused a single LB to two SB fragments,
SB1 and SB2, with a low (KD = 190 μM)
and moderate (KD = 2.5 μM) affinity
for LB, respectively. In the Zn2+-depleted state, LB can
form a complex with the high affinity SB2, which allows efficient
BRET from the complemented NLuc to the red-emitting Cy3 dye conjugated
next to SB2. Upon Zn2+ binding to the Atox1 and WD4 Zn2+-binding domains, the interaction between SB2 and LB is disrupted,
allowing for subsequent formation of a complex between LB and SB1,
which produces predominantly blue light.To cover a range of
different Zn2+ affinities, we designed three LuZi variants
based on the Zn2+-binding domains of eCALWY-1 (KD = 2 pM), eCALWY-4 (KD = 630 pM), and eCALWY-6 (KD =
2900 pM) to yield LuZi-1, LuZi-4, and LuZi-6, respectively. The presence
of cysteines in the Zn2+-binding domains precluded the
use of cysteine-maleimide chemistry to introduce the Cy3 dye. Therefore,
the noncanonical amino acid p-azidophenylalanine
(pAzF) was introduced next to the SB2 domain to allow site-specific
introduction of the Cy3 dye via strain-promoted azide–alkyne
click chemistry (SPAAC). Expression of the different LuZi variants
was successfully performed in Escherichia coli with
amber codon suppression using an orthogonal tRNA synthetase/tRNA pair
for the incorporation of the pAzF. After affinity chromatography purification,
this noncanonical amino acid was used to conjugate a DBCO-functionalized
Cy3 dye, yielding a ∼75% degree of labeling (Figure S1). LuZi-1 displayed a high red emission in the absence
of Zn2+, ensuing from efficient BRET from reconstituted
NLuc to the Cy3 dye (Figure A). Addition of Zn2+ resulted in a large decrease
in the red/blue emission ratio, which is consistent with Zn2+-binding induced disruption of the LB-SB2 interaction and subsequent
formation of the LB-SB1 complex. Zn2+ titration experiments
with LuZi-1 showed a 239% maximal change in the emission ratio upon
Zn2+ binding and yielded a KD of 12.5 ± 1.0 pM, which is similar to that of the eCALWY-1
sensor (Figure B).
LuZi-4 and LuZi-6 also showed a Zn2+ induced decrease in
the red/blue emission ratio, although the change in the emission ratio
was attenuated compared to that of LuZi-1 (74% and 36%, respectively).
Titration experiments yielded Zn2+-binding affinities of
176 ± 32 pM and 1.15 ± 0.1 nM for LuZi-4 and LuZi-6, respectively,
which again are comparable to the Zn2+ affinities of their
parental eCALWY sensors (Figure B). The relatively modest changes in the emission ratio
observed for LuZi-4 and LuZi-6 are primarily due to the high Cy3 emission
(578 nm) in the Zn2+-saturated state, which suggests that
SB2 might still partially interact with LB in this state (Figure C). The only difference
between LuZi-1 and LuZi-4 is the replacement of one of the four Zn2+-coordinating cysteines in LuZi-1 by a serine in LuZi-4.
This substitution not only weakens the Zn2+ affinity, but
coordination by three cysteines apparently also allows for a conformation
that is still compatible with an LB-SB2 interaction, whereas coordination
by four cysteines in LuZi-1 results in a conformation that is incompatible
with the LB-SB2 interaction. We hypothesized that by reducing the
freedom of movement of the Zn2+-binding domains (Atox1
and WD4) in the Zn2+-saturated state of LuZi-4 and LuZi-6,
SB2 could be prevented from forming a complex with LB, thus suppressing
undesired BRET in the saturated state of the sensor. To do so, we
deleted four amino acids in the linker between Atox1 and five amino
acids in the linker between WD4 and SB2 (Figure S8). The resulting LuZi-4.2 and LuZi-6.2 variants were successfully
expressed, purified, and conjugated with Cy3, showing labeling efficiencies
of 84% and 63%, respectively (Figure S1). For LuZi-4.2, a substantial decrease in BRET was indeed observed
for the Zn2+-saturated state compared to that of LuZi-4,
resulting in an increase in the ratiometric response from 74% to 181%
obtaining a similar KD of 221 ± 18 pM (Figures D and 2E). Unfortunately, shortening
of the linkers did not improve the ratiometric response of the LuZi-6
sensor, with the LuZi-6.2 sensor showing emission spectra that are
very similar to that of LuZi-6 (Figures D and 2E). Furthermore,
the affinity of LuZi-6.2 for Zn2+ had slightly decreased
(KD = 708 ±
147 pM). Nonetheless, two attractive bioluminescent sensor proteins
were obtained (LuZi-1 and LuZi-4.2) that show a robust, 2-fold change
in the emission ratio and together allow quantification of free Zn2+ concentrations between 2 pM and 1 nM.
Figure 2
Performance and optimization
of the LuZi sensor proteins. (A) Bioluminescence
emission spectra (normalized to emission at 458 nm) of LuZi-1, LuZi-4,
and LuZi-6 in the Zn2+-depleted (dashed line) and Zn2+-saturated (solid line) state. (B) Bioluminescence emission
ratio (578 nm/458 nm) of the LuZi variants in the presence of a range
of free Zn2+ concentrations buffered using 1 mM HEDTA,
1 mM DHPTA, or 1 mM EGTA. LuZi-1, LuZi-4, and LuZi-6 yielded KD,app values of 12.5 ± 1.0 pM, 176 ±
32 pM, and 1.15 ± 0.1 nM, respectively (Supplementary Table 2). (C) Schematic representation of our hypothesis of
the two possible sensor conformations in the presence of Zn2+, explaining the high BRET in the Zn2+-saturated state.
(D) Bioluminescence emission spectra (normalized to emission at 458
nm) of LuZi-4.2 and LuZi-6.2 in the Zn2+-depleted (dashed
line) and Zn2+-saturated (solid line) state. The gray spectra
represent the original sensors (LuZi-4 and LuZi-6), and the colored
spectra represent the optimized variants (LuZi-4.2 and LuZi-6.2).
(E) Bioluminescence emission ratio (578 nm/458 nm) of LuZi-4.2 and
LuZi-6.2 as a function of free Zn2+ concentration. LuZi-4.2
and LuZi-6.2 yielded KD,app values of
221 ± 18 pM and 708 ± 147 pM, respectively. Measurements
were performed using 2 nM sensor protein and 1000-fold diluted NLuc
substrate in 150 mM HEPES (pH 7.1), 100 mM NaCl, 10% (v/v) glycerol,
5 μM DTT, 1 mM TCEP, and 1 mg mL–1 BSA at
20 °C. Error bars represent average ± s.d. (n = 3), and the solid lines are fitted using eq (Methods section).
Performance and optimization
of the LuZi sensor proteins. (A) Bioluminescence
emission spectra (normalized to emission at 458 nm) of LuZi-1, LuZi-4,
and LuZi-6 in the Zn2+-depleted (dashed line) and Zn2+-saturated (solid line) state. (B) Bioluminescence emission
ratio (578 nm/458 nm) of the LuZi variants in the presence of a range
of free Zn2+ concentrations buffered using 1 mM HEDTA,
1 mM DHPTA, or 1 mM EGTA. LuZi-1, LuZi-4, and LuZi-6 yielded KD,app values of 12.5 ± 1.0 pM, 176 ±
32 pM, and 1.15 ± 0.1 nM, respectively (Supplementary Table 2). (C) Schematic representation of our hypothesis of
the two possible sensor conformations in the presence of Zn2+, explaining the high BRET in the Zn2+-saturated state.
(D) Bioluminescence emission spectra (normalized to emission at 458
nm) of LuZi-4.2 and LuZi-6.2 in the Zn2+-depleted (dashed
line) and Zn2+-saturated (solid line) state. The gray spectra
represent the original sensors (LuZi-4 and LuZi-6), and the colored
spectra represent the optimized variants (LuZi-4.2 and LuZi-6.2).
(E) Bioluminescence emission ratio (578 nm/458 nm) of LuZi-4.2 and
LuZi-6.2 as a function of free Zn2+ concentration. LuZi-4.2
and LuZi-6.2 yielded KD,app values of
221 ± 18 pM and 708 ± 147 pM, respectively. Measurements
were performed using 2 nM sensor protein and 1000-fold diluted NLuc
substrate in 150 mM HEPES (pH 7.1), 100 mM NaCl, 10% (v/v) glycerol,
5 μM DTT, 1 mM TCEP, and 1 mg mL–1 BSA at
20 °C. Error bars represent average ± s.d. (n = 3), and the solid lines are fitted using eq (Methods section).
BLZinCh-Pro: Improving Sensor Performance
by Introduction of
Polyproline Linkers
The previously developed BLZinCh-1 sensor
consisted of two fluorescent protein domains containing exterior Zn2+-coordinating residues, connected via a long linker with
18 GGS repeats. The flexibility of this linker allowed the fluorescent
proteins to form a complex in the presence of Zn2+, resulting
in efficient FRET in the Zn2+-bound state. In the Zn2+-depleted state, this sensor adopts an ensemble of different
conformations. Although the average distance between the fluorescent
domains is larger in the Zn2+-depleted state than in the
Zn2+-bound state, flexible linkers form relatively compact
ensembles, giving rise to a substantial amount of energy transfer
also in the Zn2+-depleted state.[32] Due to the high energy transfer efficiency in the Zn2+-bound state, this was not a problem when measuring FRET (ratiometric
change of ∼400%), but it severely affected the BRET response.[23] Therefore, to increase the distance between
the fluorescent proteins in the Zn2+-depleted state, we
developed the BLZinCh-Pro series of bioluminescent Zn2+ sensors in which the flexible (GGS)18 linker was replaced
by rigid polyproline linkers of different lengths. We first incorporated
a 50x proline linker (BLZinCh-P50) in the BLZinCh-1 backbone and subsequently
used digestion with the restriction enzyme BseRI to generate three
other variants: BLZinCh-P20, BLZinCh-P30, and BLZinCh-P40, with respectively
20, 30, or 40 prolines in the linker (Figures C, S3, S6, and S7).Following successful expression and purification of the
BLZinCh-Pro sensors (Figure S2), bioluminescent
spectra were obtained for all variants in the absence and presence
of Zn2+. In the Zn2+-free state, a consistent
decrease of the Citrine emission (533 nm) was observed upon increasing
the linker length from 20 to 50 proline residues, with no or very
little Citrine emission observed for the sensors with the longer linkers
(Figure A). This shows
that the two fluorescent domains are more effectively separated in
the BLZinCh-Pro sensors compared to the parent BLZinCh-1 sensor, reducing
undesired FRET and BRET in the absence of Zn2+. In contrast,
very similar bioluminescence spectra were obtained in the presence
of saturating amounts of Zn2+ for BLZinCh-1, BLZinCh-P20,
BLZinCh-P30, and BLZinCh-P40, while a somewhat lower ratio was observed
for BLZinCh-P50. These results show that the BLZinCh-1 and BLZinCh-Pro
sensors form the same Zn2+-bound complex despite the more
rigid linkers in the latter, with the exception of BLZinCh-P50 where
mechanical strain may affect the relative orientation of the fluorescent
domains or preclude complete formation of the closed, high-FRET/BRET
state. As a result, introduction of the different proline linkers
resulted in an increased ratiometric response from 39% in BLZinCh-1
to 71%, 150%, 150%, and 121%, for BLZinCh-P20, -P30, -P40, and -P50,
respectively (Figure A). Introduction of the proline linkers also attenuated the Zn2+ affinity of the sensors, yielding KD,app of 543 ± 45 pM, 693 ± 57 pM, 889 ± 76
pM, and 992 ± 80 pM for BLZinCh-P20, BLZinCh-P30, BLZinCh-P40,
and BLZinCh-50, respectively (Figures B and 3C). The attenuation of
the Zn2+ affinity can be understood by the effect of linker
stiffness and linker length on the effective concentration for complex
formation. Indeed, for the 20–30 Å distance between the
linker ends in the Zn2+-bound state of the sensor, higher
effective concentrations are predicted for flexible linkers compared
to polyproline linkers.[32,33] Furthermore, a decrease
in effective linker length is expected upon increasing the length
of the stiff polyproline linker, which is in line with the small but
consistent increase in KD observed experimentally
when increasing the length of the proline linker. Importantly, the
attenuation of the Zn2+ affinity from 160 pM in the parental
BLZinCh-1 to the 0.5–1 nM affinities for the BLZinCh-Pro sensors
makes the latter better suited for measuring intracellular cytosolic
Zn2+ and free Zn2+ in serum.
Figure 3
Performance of the BLZinCh-Pro
sensor proteins. (A) Bioluminescence
emission spectra (normalized to emission at 475 nm) of the BLZinCh-1
and BLZinCh-Pro variants in the Zn2+-depleted (dashed line)
and Zn2+-saturated (solid line) state. (B) Bioluminescence
emission ratio (533 nm/473 nm) of the BLZinCh-Pro variants in the
presence of a range of free Zn2+ concentrations buffered
using 1 mM DHPTA, 1 mM EGTA, or 1 mM NTA. Measurements were performed
using 0.2 nM sensor protein and 2000-fold diluted NLuc substrate in
150 mM HEPES (pH 7.1), 100 mM NaCl, 10% (v/v) glycerol, 5 μM
DTT, 1 mM TCEP, and 1 mg mL–1 BSA at 20 °C
(Supplementary Table 2). Each data point
is the average of three measurements ± standard deviation (s.d.),
and the solid lines are fitted using eq (Methods section). (C) Maximal
change in the emission ratio and affinity for Zn2+ of each
BLZinCh-Pro variant. Bars represent average values ± standard
deviation (s.d.).
Performance of the BLZinCh-Pro
sensor proteins. (A) Bioluminescence
emission spectra (normalized to emission at 475 nm) of the BLZinCh-1
and BLZinCh-Pro variants in the Zn2+-depleted (dashed line)
and Zn2+-saturated (solid line) state. (B) Bioluminescence
emission ratio (533 nm/473 nm) of the BLZinCh-Pro variants in the
presence of a range of free Zn2+ concentrations buffered
using 1 mM DHPTA, 1 mM EGTA, or 1 mM NTA. Measurements were performed
using 0.2 nM sensor protein and 2000-fold diluted NLuc substrate in
150 mM HEPES (pH 7.1), 100 mM NaCl, 10% (v/v) glycerol, 5 μM
DTT, 1 mM TCEP, and 1 mg mL–1 BSA at 20 °C
(Supplementary Table 2). Each data point
is the average of three measurements ± standard deviation (s.d.),
and the solid lines are fitted using eq (Methods section). (C) Maximal
change in the emission ratio and affinity for Zn2+ of each
BLZinCh-Pro variant. Bars represent average values ± standard
deviation (s.d.).
Bioluminescent Measurement
of Free Zn2+ Concentration
in Serum
The robust change in the emission ratio of the LuZi
and BLZinCh-Pro sensors and their Zn2+ affinities in the
0.1–1 nM range make these bioluminescent sensors attractive
tools for measuring free Zn2+ concentrations in blood plasma
and serum. To date, the determination of free Zn2+ concentrations
in plasma and serum has proven to be challenging, with previous approaches
relying on either indirect measurements based on the activity of Zn2+-dependent reporter enzymes or the use of fluorescent dyes.[34] For example, Magneson and co-workers used the
activity of the enzyme phosphoglucomutase to derive a free Zn2+ concentration of 0.2 nM in blood plasma.[35] Using the ZnAF-2 fluorescent sensor dye, Soybel and co-workers
reported free Zn2+ concentration in rat serum between 1
and 3 nM,[36] whereas studies with Zinpyr-1
by Haase and co-workers yielded free Zn2+ concentration
of 0.22 ± 0.05 nM in human serum.[34] Fluorescent dyes such as ZinPyr-1 and ZnAF-2 may suffer from interaction
with other blood components such as serum albumin, which could affect
their sensor properties.[37−39] To apply the herein developed
bioluminescence-based sensors for the quantification of free Zn2+ in human blood serum, we first assessed the performance
of the LuZi sensors. To compare our results with the recent study
of Haase and co-workers using ZinPyr-1, we performed all measurements
in 2% (v/v) serum in buffer. Accordingly, we measured the emission
ratio of LuZi-1, LuZi-4.2, and LuZi-6.2 in 2% human serum in the absence
and presence of 50 mM EDTA to scavenge all Zn2+ or in the
presence of a saturating amount of Zn2+. For the latter,
addition of 8 μM ZnCl2 was found to be optimal, as
addition of higher concentrations resulted in an emission ratio similar
to that of the Zn2+ depleted state (Figure S5). Our explanation for this surprising finding is
that at high Zn2+ concentrations binding of Zn2+ to each of the metal-binding domains, Atox1 and WD4, becomes favorable
over coordination of a single Zn2+ between the two domains.
The free Zn2+ concentrations can then be calculated from
the measured emission ratios usingwhere ER, ER, and ER represent the emission ratios in
the unaltered, Zn2+-depleted, and Zn2+-saturated
state, respectively.For LuZi-1, the emission ratio obtained
in 2% serum was similar to that obtained in the presence of excess
Zn2+, showing that this sensor was fully saturated (Figure A). Thus, the high
affinity of LuZi-1 renders it unsuitable for free Zn2+ detection
in serum. In contrast, LuZi-4.2 displayed an emission ratio between
that of the Zn2+-depleted and Zn2+-saturated
state, corresponding to 80% of the sensor being bound to Zn2+, which translates into a free Zn2+ concentration of 1.2
± 0.7 nM. Unfortunately, while the affinity of LuZi-6.2 is in
the proper affinity range, the small difference in the emission ratio
observed between the Zn2+-free and Zn2+-bound
states prevented reliable determination of the free Zn2+ concentration with this sensor. Furthermore, all three LuZi sensors
displayed a smaller maximal change in the emission ratio in serum,
mainly due to a higher emission ratio for the Zn2+-depleted
state in serum compared to buffer. This higher emission ratio may
be due to interactions of serum proteins that subtly affect the equilibrium
between the putative high and low BRET Zn2+-bound states.
Figure 4
Determination
of free Zn2+ concentration in diluted
human serum. Bioluminescence emission ratio of (A) the LuZi sensors
(578 nm/458 nm) and (B) BLZinCh-Pro sensors (533 nm/ 473 nm) in 2%
(v/v) human serum in buffer. The Zn2+-depleted state was
obtained by addition of 50 mM EDTA, and the Zn2+-saturated
state was obtained with the addition of 8 μM and 2 mM ZnCl2 for LuZi and BLZinCh-Pro, respectively. Measurements were
performed with 10 nM sensor protein and 1000-fold diluted NLuc substrate
in 50 mM HEPES (pH 7.1) at 22 °C. Bars represent average values
± standard deviation (s.d.).
Determination
of free Zn2+ concentration in diluted
human serum. Bioluminescence emission ratio of (A) the LuZi sensors
(578 nm/458 nm) and (B) BLZinCh-Pro sensors (533 nm/ 473 nm) in 2%
(v/v) human serum in buffer. The Zn2+-depleted state was
obtained by addition of 50 mM EDTA, and the Zn2+-saturated
state was obtained with the addition of 8 μM and 2 mM ZnCl2 for LuZi and BLZinCh-Pro, respectively. Measurements were
performed with 10 nM sensor protein and 1000-fold diluted NLuc substrate
in 50 mM HEPES (pH 7.1) at 22 °C. Bars represent average values
± standard deviation (s.d.).As the LuZi-4.2 sensor showed an attenuated change in the emission
ratio in serum, we next explored the performance of the BLZinCh-Pro
sensors to measure the serum free Zn2+ concentration. BLZinCh-P20,
-P30, -P40, and -P50 all displayed a large change in the emission
ratio, similar to the results in buffer (Figure A). Furthermore, the sensors yielded free
Zn2+ concentrations of respectively 4.8 ± 0.6 nM,
3.8 ± 0.2 nM, 3.0 ± 0.2 nM, and 2.8 ± 0.2 nM (Figure B). It should be
noted that the value obtained for BLZinCh-P20 is less reliable, because
the sensor is almost fully saturated. The free Zn2+ concentrations
obtained with LuZi 4.2 and BLZinCh-P30, -P40, and -P50 are similar
to those previously reported using ZnAF-2 (1–3 nM) but approximately
10-fold higher than those reported using ZinPyr-1.[19] This difference might be due to undesired interaction of
the Zinpyr-1 sensor with serum components or because the affinities
of the BLZinCh-Pro and LuZi sensors in serum differ slightly from
those determined in buffer. The latter is less likely because the
LuZi and BLZinCh-Pro sensors employ different Zn2+-binding
domains. Irrespective of the exact number, the LuZi and BLZinCh-Pro
sensors provide easy-to-use new tools for the quantification of free
Zn2+ in serum and show great promise to be utilized in
a clinical setting to detect zinc deficiencies.
Bioluminescent
Quantification of Intracellular Cytosolic Free
Zn2+
An advantage of using BRET-based detection
over FRET is the ability to use a standard plate reader to measure
intracellular free Zn2+ concentrations in a population
of cells. We previously applied the BLZinCh-1 sensor to measure cytosolic
free Zn2+ levels in HeLa cells. However, the affinity and
limited change in the emission ratio of BLZinCh-1 were not optimal
to measure fluctuations in free Zn2+.[27] To characterize the intracellular performance of the BLZinCh-Pro
variants, we transiently transfected HeLa cells with each sensor variant
and used the transfected cells to determine the cytosolic free Zn2+ levels with a plate reader. For each BLZinCh-Pro sensor,
a Zn2+ concentration dependent change in the emission ratio
was observed, with a decrease in the emission ratio upon Zn2+-depletion after addition of the chelator TPEN (time point 1 in Figure A) and an increase
in the emission ratio upon addition of saturating amounts of Zn2+ in the presence of the ionophore pyrithione (time point
2 in Figure A). In
addition to confirming the successful expression of functional sensor
proteins, these results also show that the response to fluctuations
in cytosolic free Zn2+ is rapid and complete within a few
minutes. The BLZinCh-Pro sensors show a sensor occupancy between 40
and 50%, which is optimal to measure both increases and decreases
in free Zn2+ (Figure B). Not surprisingly given the relatively small differences
in affinity between the sensors, similar sensor occupancies were observed,
although the sensor occupancy of BLZinCh-P50 was indeed found to be
the lowest. Based on the sensor occupancy and the experimentally determined KD for Zn2+ binding, the concentration
of cytosolic free Zn2+ could be calculated (eq ), yielding values of 536 ±
46 pM, 738 ± 231 pM, 867 ± 75 pM, and 661 ± 59 pM for
the experiments with BLZinCh-P20, -P30, -P40, and -P50, respectively
(Figure C). These
values are in agreement with the 0.5–1 nM free Zn2+ that is typically observed for the concentration of free Zn2+ in the cytosol of mammalian cells using fluorescence-based
sensors and probes.[21,40,41] Note that the BLZinCh-Pro sensors are also expected to be attractive
FRET sensors for live cell imaging using fluorescence microscopy.
In comparison with the BLZinCh-1 and eZinCh-2 sensors, the BLZinCh-Pro
sensors have an affinity that is better tuned to the concentration
of free Zn2+ in the cytosol, and they also display a larger
change in the emission ratio between the Zn2+-free and
Zn2+-bound states (700% change for BLZinCh-P40 compared
to 400% for BLZinCh-1, Figure S4).
Figure 5
Monitoring
changes in cytosolic free Zn2+ in HeLa cells
expressing BLZinCh-Pro sensors. (A) Bioluminescence emission ratio
(emission 505–545 nm/emission 400–455 nm) of HeLa cells
expressing the BLZinCh-Pro sensor proteins in a resting state and
after subsequent addition of 50 μM TPEN (1), representing the
depleted state, and 350 μM Zn2+ with 10 μM
pyrithione (2), inducing the saturated state. Bioluminescence of the
cell suspension was monitored on a plate reader using the 3000-fold
diluted NLuc substrate in 20 mM HEPES (pH 7.4), 140 mM NaCl, 2.5 mM
KCl, 1.8 mM CaCl2, and 1.0 mM MgCl2, at 37 °C.
Measurements were paused for ∼1 min during the additions at
time points 1 and 2. Data points show the average of three measurements,
and the error bars represent the standard deviation (s.d.). (B) Sensor
occupancy (calculated using eq in the Methods section) of the BLZinCh-Pro
variants. (C) Intracellular free Zn2+ concentrations measured
with the different BLZinCh-Pro sensors (calculated using eq ). Bars represent average values
± standard deviation (s.d.).
Monitoring
changes in cytosolic free Zn2+ in HeLa cells
expressing BLZinCh-Pro sensors. (A) Bioluminescence emission ratio
(emission 505–545 nm/emission 400–455 nm) of HeLa cells
expressing the BLZinCh-Pro sensor proteins in a resting state and
after subsequent addition of 50 μM TPEN (1), representing the
depleted state, and 350 μM Zn2+ with 10 μM
pyrithione (2), inducing the saturated state. Bioluminescence of the
cell suspension was monitored on a plate reader using the 3000-fold
diluted NLuc substrate in 20 mM HEPES (pH 7.4), 140 mM NaCl, 2.5 mM
KCl, 1.8 mM CaCl2, and 1.0 mM MgCl2, at 37 °C.
Measurements were paused for ∼1 min during the additions at
time points 1 and 2. Data points show the average of three measurements,
and the error bars represent the standard deviation (s.d.). (B) Sensor
occupancy (calculated using eq in the Methods section) of the BLZinCh-Pro
variants. (C) Intracellular free Zn2+ concentrations measured
with the different BLZinCh-Pro sensors (calculated using eq ). Bars represent average values
± standard deviation (s.d.).
Conclusions
In conclusion, two new bioluminescent sensor
platforms were developed
that allow fast, robust, and sensitive quantification of free Zn2+ in serum and in the cytosol of mammalian cells. The LuZi
sensors, based on mutually exclusive split NLuc complementation and
BRET to a red fluorescent Cy3 dye, are modular by design and yield
a robust change in red to blue emission upon binding to Zn2+. For the second platform, we substituted the long flexible GGS linker
in the previously reported BLZinCh-1 sensor with rigid polyproline
linkers yielding four different sensor proteins with a 3–4-fold
improved change in the emission ratio and Zn2+ affinities
between 543 and 992 pM that are optimal for measuring cytosolic free
Zn2+ concentrations. Measurements with the BLZinCh-Pro
sensors and the LuZi-4.2 sensor revealed similar values for the concentration
of free Zn2+ in (diluted) serum of 1–3 nM. The dual
readout BRET/FRET BLZinCh-Pro sensors were also shown to be ideal
for intracellular free Zn2+ measurements, providing an
attractive alternative for more complex and expensive methods based
on live cell imaging using fluorescence microscopy or FACS. The metal
selectivities of the LuZi and BLZinCh-Pro sensors will be the same
as those of their parent sensor proteins, eCALWY and eZinCh2, respectively.
Previous work on the eCALWY sensors showed interference by Cu+, Pb2+, and Cd2+, but no interference
by physiologically relevant concentrations of Ca2+, Mg2+, Fe2+, Ni2+, and Cu2+.
Moreover, mutation of one of the four coordinating cysteine residues
in eCALWY4-6 also abrogated Cu+ binding.[22,24] The metal specificity of eZinCh-2 also showed interference by soft
bivalent ions such as Pb2+ and Cd2+, but no
interference by physiologically relevant metal ions such as Ca2+, Mg2+, Fe2+, Co2+, and
Cu2+.[23]An important aspect
in the optimization of both platforms was tuning
the length and stiffness of the linkers between the individual domains
in the sensors. The optimized polyproline linkers in the BLZinCh-Pro
platform are more rigid compared to the original flexible GGS linker,
increasing the effective distance between the fluorescent proteins
in the Zn2+-depleted state of the sensor and attenuating
the affinity for Zn2+ by decreasing the effective concentration
for complex formation. The effect of linker optimization can also
be more complex. Shortening the linker between the metal-binding domains
and the LB and SB2 domains in the LuZi sensors improved the change
in the emission ratio for LuZi-4, while the sensor properties of LuZi-6
remained unaltered. This difference can be understood by considering
the equilibrium between two Zn2+-bound states, one state
in which SB2 still interacts with the LB domain (high BRET) and one
state in which the interaction between SB2 and LB is disrupted and
LB binds to SB1 (low BRET; Figure C). The equilibrium between these two states is determined
by the relative effective concentrations of the different domains
in each complex, which in turn is determined by linker lengths and
the distances that linkers need to bridge. In the low BRET, Zn2+-bound state, the linker between the Atox1 and WD4 domains
needs to span a distance of 50 Å. We have previously shown that
the linker used in the LuZi-4 sensor (containing 18 GGS repeats) is
more favorable in this low BRET state than the linker used in the
LuZi-6 sensor (6 GGS repeats), translating into an at least 10-fold
higher effective concentration for complex formation.[42] However, if the distance that this linker needs to bridge
is smaller in the high-BRET, Zn2+-bound state, this state
will become relatively more favorable for the sensor with a shorter
linker.[32] These effects are likely to be
subtle and also be determined by the relative stability of Zn2+ binding in each of the two conformational states. It is
important to emphasize that while the existence of two different Zn2+-bound conformational states provides a model for explaining
the observed effects of linker lengths on sensor properties, additional
biophysical studies are required to provide more direct evidence for
these two conformational states.The LuZi-4.2, BLZinCh-P30,
BLZinCh-P40, and BLZinCh-P50 sensors
provide attractive tools for measuring free Zn2+ concentrations
in blood plasma and serum. Compared to fluorescence-based sensors,
these bioluminescent sensors do not require external illumination,
making them well suited for integration in cheap and easy-to-use paper-based
devices or microfluidic chips with a simple mobile phone as the readout
method.[19,43,44] Because the
LuZi sensors are based on complementation of split NanoLuc, their
brightness is approximately 10-fold lower than that of the BLZinCh-Pro
sensors, which might become a disadvantage when measuring in very
small volumes. At present, the affinities of the bioluminescent sensors
are at the high end of the physiologically relevant range, which may
make it challenging to reliably measure elevated concentrations of
free Zn2+. Further decreasing the Zn2+ affinities
to a KD of ∼5 nM would thus be
of interest. This might be achieved by a comprehensive screening of
linker lengths and linker rigidity to increase the dynamic range of
the LuZi-6 sensor (see above) or by further attenuating the Zn2+ affinity of the BLZinCh-Pro sensors by more direct fusion
of the rigid proline linkers to the Cerulean and Citrine domains.
The link between free Zn2+ and the overall Zn2+ status remains unclear. By providing an easy-to-use and cheap method
to measure free Zn2+ concentrations, these sensors provide
an opportunity to establish whether the concentration of free Zn2+ is a better biomarker for zinc nutritional status than the
total zinc concentration currently determined using AAS or ICP-MS.
In addition, the bioluminescent sensors reported here also represent
attractive tools to determine free Zn2+ concentrations
in other complex media including saliva, cerebrospinal fluid, and
milk.
Methods
Expression and Purification
of Sensor Proteins
The
construction of the expression plasmids is described in the Supporting Information. The plasmids encoding
the LuZi sensors were cotransformed into E. coli BL21
(DE3) competent bacteria (Novagen) together with the pEVOL plasmid
encoding the tRNA/tRNA synthetase pair for the incorporation of the
unnatural amino acid pAzF. The pEVOL vector was a gift from Peter
Schultz (Addgene plasmid #31186).[45] Single
colonies were picked and used to inoculate 8 mL 2YT medium cultures
supplemented with 30 μg/mL kanamycin and 25 μg/mL chloramphenicol,
which were grown overnight at 37 °C and 250 rpm. Subsequently,
the cultures were transferred into 1 L 2YT cultures containing 30
μg/mL kanamycin and 25 μg/mL chloramphenicol and were
grown at 37 °C and 160 rpm until an OD600 of 0.6.
Expression was induced using 0.1 mM isopropyl β-d-1-thiogalactopyranoside
(IPTG) and 0.2% arabinose in the presence of 1 mM pAzF (Bachem, F-3075.0001),
and the induced cultures were further grown overnight at 18 °C
and 160 rpm. The bacteria were harvested and lysed using the BugBuster
reagent (Novagen) supplemented with Benzonase (Novagen). The obtained
sensor proteins were purified using Ni-NTA affinity chromatography
followed by Strep-Tactin purification according to the manufacturer’s
instructions. The protein purity was confirmed by SDS-PAGE (Figure S1), and the proteins were stored at −80
°C until further use.The pET28a plasmids encoding the
BLZinCh-Pro sensors were transformed into E. coli BL21 (DE3) competent bacteria. Single colonies were picked and used
to inoculate 8 mL LB medium cultures supplemented with 30 μg/mL
kanamycin, which were grown overnight at 37 °C and 250 rpm. Subsequently,
the cultures were transferred into 1 L LB cultures containing 30 μg/mL
kanamycin and were grown at 37 °C and 160 rpm until an OD600 of 0.6. Expression was induced using 0.5 mM IPTG, and the
induced cultures were further grown overnight at 18 °C and 160
rpm. The sensor proteins were purified as described above; however,
1 mM tris(2-carboxyethyl)phosphine (TCEP, Sigma-Aldrich) was supplemented
to the lysis reagent and to all wash and elution buffers. In addition,
50 μM DL-dithiothreitol (DTT, Sigma-Aldrich) was added to the
Strep-Tactin elution buffer (Figure S2).
In the end, the Strep-Tactin elution was concentrated and exchanged
with 150 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES,
pH 7.1), 100 mM NaCl, 10% (v/v) glycerol, 50 μM DTT, and 1 mM
TCEP using Amicon Ultra-4 Centrifugal Filter Units (molecular weight
cutoff 10 kDa, Millipore).
Fluorophore Labeling
The purified
LuZi sensor proteins
were conjugated with DBCO-Sulfo-Cy3 (Lumiprobe, 113F0) in a 30-fold
molar excess overnight at RT. Subsequently, the excess dye was removed
using an Amicon Ultra-4 centrifugal filter (molecular weight cutoff
10 kDa; Millipore). The dye-to-protein ratio was calculated using eq . The absorbance (A) of the protein and dye was measured at 280 and 555 nm,
respectively, using the UV–vis mode of NanoDrop 1000 with a
path length (L) of 0.1 cm. The extinction coefficients
(ε) of 32,890 M–1 cm–1 and
151,000 M–1 cm–1 for the protein
and dye, respectively, were determined using the ProtParam tool of
ExPASy. A correction factor (CF) of 0.06 was used to correct for the
absorbance of the dye at 280 nm.
Sensor Characterization
Bioluminescence emission spectra
were measured in a white flat-bottom 384-well plate (Nunc, Thermo
Scientific) using the Tecan Spark plate reader and an integration
time of 100 ms. Measurements were carried out in a 20 μL volume
with the 2 nM sensor protein for the LuZi sensor proteins and 0.2
nM for the BLZinCh-Pro sensor proteins in a buffer consisting of 150
mM HEPES (pH 7.1), 100 mM NaCl, 10% (v/v) glycerol, 5 μM DTT,
and 1 mM TCEP. Different concentrations of ZnCl2 were added
together with different Zn2+ chelators depending on the
concentration range measured. One mM ethylenediaminetetraacetic acid
(EDTA) was used to measure in the low picomolar concentrations, 1
mM N-(2-hydroxyethyl)ethylenediamine-N,N′,N′-triacetic
acid (HEDTA) was used for higher picomolar concentrations, and 1 mM
1,3-diamino-2-hydroxypropane-N,N,N′,N′-tetraacetic
acid (DHPTA) was used to measure in the high picomolar range. One
mM ethylene glycol-bis(2-aminoethyl ether)-N,N,N′,N′-tetraacetic
acid (EGTA) was used to measure in the nanomolar range. All chelators
were obtained from Sigma-Aldrich. The free Zn2+ concentrations
for each chelator and a certain ZnCl2 concentration were
calculated with the program MaxChelator using the stability constants
present within the program, as previously described.[22] The mixed samples were incubated for 15–20 min,
followed by the addition of the 1000-fold diluted NLuc substrate (Promega,
N1110) for the LuZi sensors and the 3200-fold diluted NLuc substrate
for the BLZinCh-Pro sensors. The KD was determined by fitting the bioluminescence emission ratio
using eq . [Zn2+] represents the calculated free Zn2+ concentration, P1
is the difference between the ratio in the Zn2+-saturated
and Zn2+-depleted state, and P2 is the emission ratio in
the Zn2+-depleted state.
Serum Measurements
The measurements in serum (Sigma-Aldrich,
H4522) were performed in a white flat-bottom 384-well plate with a
sample volume of 20 μL using the 10 nM sensor and 1000×
diluted NLuc substrate. Serum was 50 times diluted with 50 mM HEPES
(pH 7.1). The Zn2+-depleted state was created by adding
50 mM EDTA, and the Zn2+-saturated state was created by
addition of 8 μM ZnCl2 for the LuZi sensors and 2
mM ZnCl2 for the BLZinCh-Pro sensors. All samples were
prepared in triplicate, and the luminescence was measured directly
after adding the substrate, using the Tecan Spark plate reader. The
free Zn2+ concentration was calculated using eq .
Cytosolic Free Zn2+ Measurements
Cell culture,
transfection, and bioluminescent measurements were executed as described
in ref (30). In short,
HeLa cells were grown in Dulbecco’s Modified Eagle Medium (DMEM)
supplemented with 4.5 g/L d-glucose, 0.58 g/L l-glutamine,
10% fetal bovine serum (FBS), 100 U/mL penicillin, and 100 μg/mL
streptomycin (all from Life Technologies) at 37 °C and 5% CO2 in Falcon corning T75 culture flasks (REF 353136). One day
before transfection, 140 000 cells were seeded in a six-well plate
(Corning). When cells reached ∼80% confluency, the cells were
transfected with 2 μg of pCMV-BLZinCh-1, -P20, -P30, -P40, or
-P50 and 3 μL of Lipofectamine 3000 (Life Technologies) in Opti-MEM
Reduced Serum Medium (Life Technologies). After 6 h, the medium was
refreshed with DMEM. Two days after transfection, trypsin (Thermo
Fisher Scientific) was used to release the cells from the wells, and
the cells were subsequently resuspended in 1 mL of imaging buffer
(20 mM HEPES (pH 7.4), 140 mM NaCl, 2.5 mM KCl, 1.8 mM CaCl2, and 1.0 mM MgCl2). Fifteen microliters of the HeLa cells
was transferred to a 96-well plate (Nunc, Thermo Scientific) to which
buffer was added to make a final volume of 150 μL. The NLuc
substrate in a final 3000-fold dilution was added, and bioluminescence
was monitored on a Tecan Spark 10 M plate reader using filters for
the detection of NLuc-Cerulean (400–455 nm) and Citrine (500–545
nm) emission. Integration times of 1 s were used, and the temperature
was set at 37 °C. The measurement was performed for 50 min, during
which 50 μM N,N,N′,N′-tetrakis(2-pyridylmethyl)ethylenediamine
(TPEN, Sigma-Aldrich) was added to the cells after 17 min, and 350
μM ZnCl2 and 10 μM 2-mercaptopyridine N-oxide (pyrithione, Acros Organics) were added after 33
min. Sensor occupancies were calculated using eq , and the Zn2+ levels were calculated
using eq . Rmin and
Rmax represent the steady-state emission ratios after the addition
of TPEN and Zn2+/pyrithione, respectively, and R is the steady-state emission ratio of the cells in the
resting state.
Authors: Janet C King; Kenneth H Brown; Rosalind S Gibson; Nancy F Krebs; Nicola M Lowe; Jonathan H Siekmann; Daniel J Raiten Journal: J Nutr Date: 2015-04-01 Impact factor: 4.798
Authors: Jason W Chin; Stephen W Santoro; Andrew B Martin; David S King; Lei Wang; Peter G Schultz Journal: J Am Chem Soc Date: 2002-08-07 Impact factor: 15.419